eflornithine has been researched along with Neoplasms in 51 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thus, DFMO may sensitize tumors to other therapeutics, including immunotherapies and chemotherapies." | 2.82 | Polyamine Depletion Strategies in Cancer: Remodeling the Tumor Immune Microenvironment to Enhance Anti-Tumor Responses. ( Bieberich, CJ; Casero, RA; Chin, A; Stewart, TM, 2022) |
| "Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female." | 2.61 | Hirsutism in Women. ( Bain, J; Matheson, E, 2019) |
| "Putrescine plays a very important role in the regulation of division, differentiation and maturation of cells as well as apoptosis." | 2.50 | [The importance of putrescine in the human body]. ( Lachowski, M; Zdrojewicz, Z, 2014) |
| "Hirsutism is defined as excess hair growth in androgen-dependent areas of the body in women." | 2.46 | Hirsutism: Diagnosis and management. ( Brodell, LA; Mercurio, MG, 2010) |
| "Recent clinical cancer chemoprevention trials, using dose de-escalation designs, indicate that DFMO can be given over long periods of time at low doses that suppress polyamine contents in gastrointestinal and other epithelial tissues but cause no detectable hearing loss or other side effects." | 2.40 | Development of difluoromethylornithine (DFMO) as a chemoprevention agent. ( Gerner, EW; Meyskens, FL, 1999) |
| "Although most experimental cancer models responds strikingly to treatment with polyamine antimetabolites--namely, inhibitors of various polyamine synthesizing enzymes--a real breakthrough in the treatment of human cancer has not yet occurred." | 2.38 | Polyamines: from molecular biology to clinical applications. ( Alhonen, L; Jänne, J; Leinonen, P, 1991) |
| "Because the cytotoxicity of most anti-cancer drugs can be attributed to inhibitory effects on DNA synthesis and cell replication it led to speculation that inhibition of polyamine synthesis could be a useful tool in the control of neoplastic growth." | 2.37 | The chemotherapeutic potential of polyamine antimetabolites. ( Kingsnorth, AN, 1986) |
| "Furthermore, transformed and cancer cells, possibly because of their higher proliferative rate, appear to be more dependent on polyamine metabolism than their normal counterparts." | 2.37 | Polyamines in normal and cancer cells. ( Casero, RA; Luk, GD, 1987) |
| "Several different classes of other anticancer agents may under some conditions exert enhanced effects when polyamine levels are depleted." | 2.37 | Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. ( Pegg, AE, 1988) |
| "To test this hypothesis, we treated tumors with DFMO, in either the presence or absence of additional PD-1 blockade, and subsequently analyzed their immunological and therapeutic responses." | 1.62 | Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. ( Bartee, E; Dryja, P; Fisher, C; Woster, PM, 2021) |
| "Hypoxia is a hallmark of solid tumors, which may offer opportunities for targeted therapies of cancer; however, the mechanisms that link hypoxia to malignant transformation and tumor progression are not fully understood." | 1.35 | Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase. ( Belting, M; Bengtson, P; Bjurberg, M; Kucharzewska, P; Påhlman, S; Persson, L; Svensson, KJ; Ten Dam, GB; Welch, JE, 2008) |
| " However, drug combination therapies expected to potentiate the effects of these drugs have yet to be systematically pursued." | 1.32 | The role of polyamines in human cancer: prospects for drug combination therapies. ( Bachmann, AS, 2004) |
| "Early randomized Phase II cancer chemoprevention trials which assess short-term biological activity are critical to the decision process to advance to late Phase II/Phase III trials." | 1.30 | Bayesian monitoring of phase II trials in cancer chemoprevention. ( Beenken, SW; Cronin, KA; Freedman, LS; Kelloff, GJ; Lieberman, R; Weiss, HL, 1999) |
| "One patient with colon cancer experienced a greater than 50% decrease in measurable disease but developed severe myelotoxicity." | 1.27 | Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)]. ( Burchenal, JH; Coonley, CJ; Warrell, RP, 1983) |
| "This method is applied to cancer patients treated by cytotoxic chemotherapy with or without difluoromethylornithine (DFMO)." | 1.27 | Determination of free and total polyamines in human serum and urine by ion-pairing high-performance liquid chromatography using a radial compression module. Application to blood polyamine determination in cancer patients treated or not treated with an orn ( Belleville, F; Brossat, B; Metz, R; Nabet, P; Straczek, J, 1983) |
| " DFMO levels were measured using an ion exchange chromatographic assay and pharmacokinetic studies were performed in patients treated at each dose level." | 1.27 | Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis. ( Abeloff, MD; Baylin, SB; Blanc, O; Griffin, CA; Hermann, J; Luk, GD; Sjoerdsma, A; Slavik, M, 1984) |
| "in seven cancer patients over 10-day courses at doses of 10-90 g/day and 24-h urinary excretion of polyamines and decarboxylated-S-adenosylmethionine was determined before, during, and after treatment." | 1.27 | Decarboxylated-S-adenosylmethionine excretion: a biochemical marker of ornithine decarboxylase inhibition by alpha-difluoromethylornithine. ( Haegele, KD; Romijn, JC; Schechter, PJ; Sjoerdsma, A; Splinter, TA, 1987) |
| " Pharmacokinetic studies demonstrated that the intravenous schedules achieved higher plasma levels of DFMO than those previously obtained with chronic oral dosing." | 1.27 | Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine. ( Abeloff, MD; Baylin, SB; Blanc, O; Chien, SC; Griffin, CA; Hermann, J; Luk, GD; Slavik, M; Thompson, G, 1987) |
| " Plating efficiency assays were used to generate BCNU dose-response survival curves for DFMO-treated and control cells." | 1.27 | Chemosensitization of cultured human carcinoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by difluoromethylornithine-induced polyamine depletion. ( Komar, KA; Seidenfeld, J, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (37.25) | 18.7374 |
| 1990's | 15 (29.41) | 18.2507 |
| 2000's | 9 (17.65) | 29.6817 |
| 2010's | 5 (9.80) | 24.3611 |
| 2020's | 3 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Chin, A | 1 |
| Bieberich, CJ | 1 |
| Stewart, TM | 1 |
| Casero, RA | 3 |
| Hyvönen, MT | 1 |
| Khomutov, M | 1 |
| Vepsäläinen, J | 1 |
| Khomutov, AR | 1 |
| Keinänen, TA | 1 |
| Dryja, P | 1 |
| Fisher, C | 1 |
| Woster, PM | 1 |
| Bartee, E | 1 |
| Cho, HE | 1 |
| Kang, MH | 1 |
| Matheson, E | 1 |
| Bain, J | 1 |
| Zdrojewicz, Z | 1 |
| Lachowski, M | 1 |
| Alexiou, GA | 1 |
| Lianos, GD | 1 |
| Ragos, V | 1 |
| Galani, V | 1 |
| Kyritsis, AP | 1 |
| Svensson, KJ | 1 |
| Welch, JE | 1 |
| Kucharzewska, P | 1 |
| Bengtson, P | 1 |
| Bjurberg, M | 1 |
| Påhlman, S | 1 |
| Ten Dam, GB | 1 |
| Persson, L | 1 |
| Belting, M | 1 |
| Brodell, LA | 1 |
| Mercurio, MG | 1 |
| Chen, X | 1 |
| Li, N | 1 |
| Wang, S | 1 |
| Hong, J | 1 |
| Fang, M | 1 |
| Yousselfson, J | 1 |
| Yang, P | 1 |
| Newman, RA | 1 |
| Lubet, RA | 2 |
| Yang, CS | 1 |
| Gerner, EW | 3 |
| Meyskens, FL | 2 |
| Bachmann, AS | 1 |
| Huang, Y | 1 |
| Pledgie, A | 1 |
| Davidson, NE | 1 |
| Ranger-Moore, J | 1 |
| Alberts, DS | 2 |
| Montironi, R | 1 |
| Garcia, F | 1 |
| Davis, J | 1 |
| Frank, D | 1 |
| Brewer, M | 1 |
| Mariuzzi, GM | 1 |
| Bartels, HG | 1 |
| Bartels, PH | 1 |
| Ignatenko, NA | 1 |
| Lance, P | 1 |
| Hurley, LH | 1 |
| Smith, KJ | 1 |
| Skelton, H | 1 |
| Raul, F | 1 |
| Warrell, RP | 2 |
| Burchenal, JH | 2 |
| Coonley, CJ | 1 |
| Heby, O | 2 |
| Brossat, B | 1 |
| Straczek, J | 1 |
| Belleville, F | 1 |
| Nabet, P | 1 |
| Metz, R | 1 |
| Abeloff, MD | 2 |
| Slavik, M | 2 |
| Luk, GD | 3 |
| Griffin, CA | 2 |
| Hermann, J | 2 |
| Blanc, O | 2 |
| Sjoerdsma, A | 2 |
| Baylin, SB | 2 |
| Oredsson, SM | 1 |
| Marton, LJ | 2 |
| Bardocz, S | 1 |
| Takahashi, Y | 1 |
| Nishioka, K | 1 |
| Pegg, AE | 3 |
| Kelloff, GJ | 4 |
| Crowell, JA | 1 |
| Boone, CW | 2 |
| Steele, VE | 1 |
| Greenwald, P | 1 |
| Covey, JM | 1 |
| Doody, LA | 1 |
| Knapp, GG | 1 |
| Ganju, V | 1 |
| Edmonson, JH | 2 |
| Buckner, JC | 2 |
| Wallace, HM | 1 |
| Ziegler, J | 1 |
| Von Hoff, DD | 1 |
| Cronin, KA | 1 |
| Freedman, LS | 1 |
| Lieberman, R | 1 |
| Weiss, HL | 1 |
| Beenken, SW | 1 |
| McCann, PP | 1 |
| Jänne, J | 1 |
| Alhonen, L | 1 |
| Leinonen, P | 1 |
| Breau, JL | 1 |
| Saydjari, R | 1 |
| Alexander, RW | 1 |
| Upp, JR | 1 |
| Barranco, SC | 1 |
| Townsend, CM | 1 |
| Thompson, JC | 1 |
| Malone, WF | 2 |
| Sigman, CC | 1 |
| Fay, JR | 1 |
| Kingsnorth, AN | 1 |
| Splinter, TA | 2 |
| Romijn, JC | 2 |
| Haegele, KD | 1 |
| Schechter, PJ | 1 |
| Chien, SC | 1 |
| Thompson, G | 1 |
| Kovach, JS | 2 |
| Kvols, LK | 1 |
| Hahn, RG | 1 |
| Svingen, PA | 1 |
| Ogawa, M | 1 |
| Seidenfeld, J | 2 |
| Komar, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes[NCT05594563] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-03-14 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for eflornithine and Neoplasms
| Article | Year |
|---|---|
Polyamine Depletion Strategies in Cancer: Remodeling the Tumor Immune Microenvironment to Enhance Anti-Tumor Responses.
Topics: Animals; Cell Proliferation; Eflornithine; Neoplasms; Polyamines; Tumor Microenvironment | 2022 |
Hirsutism in Women.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Antineoplastic Agents, Hormonal; Contraceptiv | 2019 |
[The importance of putrescine in the human body].
Topics: Apoptosis; Cell Differentiation; Cell Division; Cell Membrane; Eflornithine; Hirsutism; Homeostasis; | 2014 |
Difluoromethylornithine in cancer: new advances.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, | 2017 |
Hirsutism: Diagnosis and management.
Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diag | 2010 |
Polyamines and cancer: old molecules, new understanding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Chemoprevention; Colorectal Neoplasm | 2004 |
Molecular mechanisms of polyamine analogs in cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Eflornithine; Humans; Molecular Conformation; Neoplasms; | 2005 |
A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene.
Topics: Adenomatous Polyposis Coli Protein; Antineoplastic Agents; Aspirin; Base Sequence; Colonic Neoplasms | 2005 |
alpha-Difluoromethylornithine, a polyamine inhibitor: its potential role in controlling hair growth and in cancer treatment and chemo-prevention.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Transformation, Neoplastic; Ef | 2006 |
Methylglyoxal-bis(guanylhydrazone) (Methyl-GAG): current status and future prospects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemical Phenomena; Chemistry; Clinical Tri | 1983 |
The role of dietary polyamines.
Topics: Cadaverine; Cell Division; Diet; Digestive System; DNA; Eflornithine; Humans; Neoplasms; Protein Bio | 1993 |
Polyamines as targets for therapeutic intervention.
Topics: Adenosylmethionine Decarboxylase; Biological Transport; Combined Modality Therapy; DNA; Eflornithine | 1995 |
Polyamines in human health.
Topics: Chemoprevention; Eflornithine; Homeostasis; Humans; Neoplasms; Parasitic Diseases; Polyamines | 1996 |
Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cell Division; Cell Trans | 1999 |
Ornithine decarboxylase as an enzyme target for therapy.
Topics: Amino Acid Sequence; Animals; Autoimmune Diseases; Eflornithine; Humans; Molecular Sequence Data; Ne | 1992 |
Polyamines: from molecular biology to clinical applications.
Topics: Adenosylmethionine Decarboxylase; Animals; Biogenic Polyamines; Cell Division; Eflornithine; Humans; | 1991 |
Progress in applied chemoprevention research.
Topics: Animals; Antineoplastic Agents; Dehydroepiandrosterone; Drug Evaluation; Eflornithine; Fenretinide; | 1990 |
The chemotherapeutic potential of polyamine antimetabolites.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Body Weight; Cell Division; Cell Line; Child; Drug | 1986 |
Polyamines in normal and cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Division; Eflornithine; Humans; Mice; Neoplasms; Polyamines; Ra | 1987 |
Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy.
Topics: Animals; Eflornithine; Humans; Neoplasms; Ornithine Decarboxylase Inhibitors; Polyamines | 1988 |
[Current status of clinical results of new antitumor drugs].
Topics: Aminoacridines; Amsacrine; Anthracyclines; Anthraquinones; Antibiotics, Antineoplastic; Antineoplast | 1985 |
Ornithine decarboxylase as target of chemotherapy.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Cloning, Molecular; DNA; Drug Resistance; Eflornith | 1985 |
2 trials available for eflornithine and Neoplasms
| Article | Year |
|---|---|
Methylglyoxal-bis(guanylhydrazone) (Methyl-GAG): current status and future prospects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemical Phenomena; Chemistry; Clinical Tri | 1983 |
Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy.
Topics: Doxorubicin; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Eflornithine; Fatigue; Fe | 1994 |
28 other studies available for eflornithine and Neoplasms
| Article | Year |
|---|---|
α-Difluoromethylornithine-Induced Cytostasis is Reversed by Exogenous Polyamines, Not by Thymidine Supplementation.
Topics: Animals; Cells, Cultured; Cytostatic Agents; Eflornithine; Humans; Mice; Neoplasms; Ornithine Decarb | 2021 |
Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade.
Topics: Animals; Antibodies, Monoclonal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytokines; Drug Syner | 2021 |
pH gradient-liquid chromatography tandem mass spectrometric assay for determination of underivatized polyamines in cancer cells.
Topics: Cell Line, Tumor; Chromatography, Liquid; Eflornithine; Humans; Limit of Detection; Linear Models; N | 2018 |
Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevaciz | 2008 |
Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Animals; Arachidonic Acid; Body Weight; Cyclooxygenase 2 | 2002 |
The role of polyamines in human cancer: prospects for drug combination therapies.
Topics: Amidines; Antineoplastic Combined Chemotherapy Protocols; Eflornithine; Humans; Indans; Neoplasms; P | 2004 |
Karyometry in the early detection and chemoprevention of intraepithelial lesions.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Disease Progression; | 2005 |
Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Eflornithi | 2007 |
Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)].
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Therapy, Combination; Eflornithine; Guanid | 1983 |
Cell cycle phase specificity and therapeutic effectiveness of polyamine synthesis inhibitors.
Topics: Animals; Cell Cycle; Eflornithine; Humans; Neoplasms; Ornithine; Ornithine Decarboxylase Inhibitors; | 1983 |
Determination of free and total polyamines in human serum and urine by ion-pairing high-performance liquid chromatography using a radial compression module. Application to blood polyamine determination in cancer patients treated or not treated with an orn
Topics: Aged; Cadaverine; Chromatography, High Pressure Liquid; Eflornithine; Female; Fluorescence; Humans; | 1983 |
Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Eflornithine; Humans; Kinetics; Middle Aged; Ne | 1984 |
Potential uses of polyamine biosynthesis inhibitors in tumor therapy.
Topics: Animals; Antineoplastic Agents; Cell Cycle; DNA Repair; Drug Therapy, Combination; Eflornithine; Hum | 1984 |
Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy.
Topics: Animals; Antineoplastic Agents; Eflornithine; Humans; Neoplasms; Neoplasms, Experimental; Rats; Surv | 1995 |
Clinical development plan: 2-difluoromethylornithine (DFMO).
Topics: Animals; Clinical Trials as Topic; Dogs; Drug Approval; Eflornithine; Humans; Mice; Neoplasms; Rats | 1994 |
"Sweet sixteen" drugs blur line between treatment, prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dru | 1997 |
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Efl | 1998 |
Bayesian monitoring of phase II trials in cancer chemoprevention.
Topics: Antineoplastic Agents; Bayes Theorem; Chemoprevention; Clinical Trials, Phase II as Topic; Data Inte | 1999 |
[New antiproliferative agents].
Topics: Cholecalciferol; Drug Synergism; Eflornithine; Humans; Neoplasms; Somatostatin; Tretinoin; Vitamin A | 1990 |
Differential sensitivity of various human tumors to inhibition of polyamine biosynthesis in vivo.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Eflornithine; Humans; Mice; Mice, Inbred BALB | 1991 |
Chemoprevention strategies utilizing combinations of inhibitors of carcinogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Eflornithine; Humans; Neoplasm | 1989 |
Phase I study of alpha-difluoromethylornithine and methyl-GAG.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Deafness | 1986 |
Decarboxylated-S-adenosylmethionine excretion: a biochemical marker of ornithine decarboxylase inhibition by alpha-difluoromethylornithine.
Topics: Aged; Creatinine; Eflornithine; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms; Ornithine De | 1987 |
Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine.
Topics: Administration, Oral; Adult; Aged; Drug Evaluation; Eflornithine; Half-Life; Humans; Injections, Int | 1987 |
Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Eflornithine; Female; Humans; Interferon alpha- | 1988 |
Enhancement of the antiproliferative activity of human interferon by polyamine depletion.
Topics: Aspirin; Cell Division; Cell Line; Doxorubicin; Drug Synergism; Eflornithine; Humans; Indomethacin; | 1985 |
Chemosensitization of cultured human carcinoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by difluoromethylornithine-induced polyamine depletion.
Topics: Carmustine; Cell Division; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Eflorni | 1985 |
Effects of difluoromethylornithine on proliferation, polyamine content and plating efficiency of cultured human carcinoma cells.
Topics: Cell Division; Cell Line; Clone Cells; Eflornithine; Female; Humans; Kinetics; Neoplasms; Ornithine; | 1985 |